NEW YORK, September 11, 2017 /PRNewswire/ --
If you want a Stock Review on ACOR, ADXS, XBIT, or AKBA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, September 08, 2017, the NASDAQ Composite ended the trading session at 6,360.19, down 0.59%; the Dow Jones Industrial Average edged 0.06% higher, to finish at 21,797.79; and the S&P 500 closed at 2,461.43, slightly dropping 0.15%. US markets saw five out of nine sectors finishing the day in green and four in red. This Monday, DailyStockTracker.com has initiated reports coverage on the following Biotechnology equities: Acorda Therapeutics Inc. (NASDAQ: ACOR), Advaxis Inc. (NASDAQ: ADXS), XBiotech Inc. (NASDAQ: XBIT), and Akebia Therapeutics Inc. (NASDAQ: AKBA). Take a look at the free research reports issued today on DailyStockTracker.com for these stocks by signing up at:
http://dailystocktracker.com/register/
Acorda Therapeutics
Ardsley, New York headquartered Acorda Therapeutics Inc.'s stock finished Friday's session 2.47% higher at $22.80 with a total trading volume of 561,621 shares. The Company's shares have advanced 10.41% in the last one month, 34.91% in the previous three months, and 21.28% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.69% and 11.23%, respectively. Additionally, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have a Relative Strength Index (RSI) of 54.60. Sign up and read the free research report on ACOR at:
http://dailystocktracker.com/registration/?symbol=ACOR
Advaxis
On Friday, shares in Princeton, New Jersey-based Advaxis Inc. recorded a trading volume of 471,994 shares. The stock ended the session 2.92% higher at $7.41. The Company's shares have advanced 18.94% in the last one month. The stock is trading above its 50-day moving average by 13.04%. Moreover, shares of Advaxis, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have an RSI of 73.76. The complimentary research report on ADXS can be downloaded at:
http://dailystocktracker.com/registration/?symbol=ADXS
Xbiotech
Austin, Texas headquartered XBiotech Inc.'s shares closed the day 2.40% lower at $4.87. The stock recorded a trading volume of 30,300 shares. The Company's shares have gained 17.63% in the last month and 52.19% over the previous three months. The stock is trading above its 50-day moving averages by 1.06%. Additionally, shares of XBiotech, which engages in discovering and developing True Human monoclonal antibodies for treating various diseases, have an RSI of 48.32. Register for free on DailyStockTracker.com and access the latest report on XBIT at:
http://dailystocktracker.com/registration/?symbol=XBIT
Akebia Therapeutics
Shares in Cambridge, Massachusetts headquartered Akebia Therapeutics Inc. finished 1.94% higher at $16.78. The stock recorded a trading volume of 287,281 shares. The Company's shares have advanced 20.29% in the last one month, 20.55% in the previous three months, 99.76% over the last twelve months, and 61.19% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 15.05% and 43.33%, respectively. Furthermore, shares of Akebia Therapeutics, which focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology, have an RSI of 69.66. Get free access to your research report on AKBA at:
http://dailystocktracker.com/registration/?symbol=AKBA
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
Advertisement
If you want a Stock Review on ACOR, ADXS, XBIT, or AKBA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, September 08, 2017, the NASDAQ Composite ended the trading session at 6,360.19, down 0.59%; the Dow Jones Industrial Average edged 0.06% higher, to finish at 21,797.79; and the S&P 500 closed at 2,461.43, slightly dropping 0.15%. US markets saw five out of nine sectors finishing the day in green and four in red. This Monday, DailyStockTracker.com has initiated reports coverage on the following Biotechnology equities: Acorda Therapeutics Inc. (NASDAQ: ACOR), Advaxis Inc. (NASDAQ: ADXS), XBiotech Inc. (NASDAQ: XBIT), and Akebia Therapeutics Inc. (NASDAQ: AKBA). Take a look at the free research reports issued today on DailyStockTracker.com for these stocks by signing up at:
Advertisement
http://dailystocktracker.com/register/
Acorda Therapeutics
Ardsley, New York headquartered Acorda Therapeutics Inc.'s stock finished Friday's session 2.47% higher at $22.80 with a total trading volume of 561,621 shares. The Company's shares have advanced 10.41% in the last one month, 34.91% in the previous three months, and 21.28% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.69% and 11.23%, respectively. Additionally, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have a Relative Strength Index (RSI) of 54.60. Sign up and read the free research report on ACOR at:
http://dailystocktracker.com/registration/?symbol=ACOR
Advaxis
On Friday, shares in Princeton, New Jersey-based Advaxis Inc. recorded a trading volume of 471,994 shares. The stock ended the session 2.92% higher at $7.41. The Company's shares have advanced 18.94% in the last one month. The stock is trading above its 50-day moving average by 13.04%. Moreover, shares of Advaxis, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have an RSI of 73.76. The complimentary research report on ADXS can be downloaded at:
http://dailystocktracker.com/registration/?symbol=ADXS
Xbiotech
Austin, Texas headquartered XBiotech Inc.'s shares closed the day 2.40% lower at $4.87. The stock recorded a trading volume of 30,300 shares. The Company's shares have gained 17.63% in the last month and 52.19% over the previous three months. The stock is trading above its 50-day moving averages by 1.06%. Additionally, shares of XBiotech, which engages in discovering and developing True Human monoclonal antibodies for treating various diseases, have an RSI of 48.32. Register for free on DailyStockTracker.com and access the latest report on XBIT at:
http://dailystocktracker.com/registration/?symbol=XBIT
Akebia Therapeutics
Shares in Cambridge, Massachusetts headquartered Akebia Therapeutics Inc. finished 1.94% higher at $16.78. The stock recorded a trading volume of 287,281 shares. The Company's shares have advanced 20.29% in the last one month, 20.55% in the previous three months, 99.76% over the last twelve months, and 61.19% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 15.05% and 43.33%, respectively. Furthermore, shares of Akebia Therapeutics, which focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology, have an RSI of 69.66. Get free access to your research report on AKBA at:
http://dailystocktracker.com/registration/?symbol=AKBA
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
